Navigation Links
Selective inhibition of BMK1 suppresses tumor growth

A study describing a newly developed pharmacological inhibitor is providing detailed insight into how an enzyme that has been implicated in multiple human malignancies regulates a known tumor suppressor. The research, published by Cell Press in the September 14th issue of the journal Cancer Cell, may have broad application for treating human cancers.

Mitogen-activated protein kinases (MAPKs) are enzymes that regulate multiple cellular activities, including proliferation and cell survival. Mutations in MAPK signaling pathways have been shown to play a significant role in many types of cancer. Of the four different MAPKs that have been identified in mammalian cells, ERK1/2 and BMK1 exhibit significant structural similarity. In fact, recent research has shown that some pharmacological compounds which have been considered to be specific inhibitors of ERK1/2, also interfere with the lesser known BMK1.

"It is critical that results using the common MAPK inhibitors be reevaluated using more specific inhibitors of the BMK1 and ERK1/2 cascades. However, so far there has been no specific small-molecule inhibitor of BMK1 that is effective both in cells and animals," explains senior study author, Dr. Jiing-Dwan Lee, from The Scripps Research Institute in La Jolla, California. "More importantly, the lack of this kind of BMK1 inhibitor has hampered the understanding of the physiological/pathological roles of BMK1."

Dr. Lee and colleagues discovered that promyelocytic leukemia protein (PML), which is a known tumor suppressor, is inhibited by BMK1. "Previous reports had implicated ERK1/2 in the regulation of PML," says Dr. Lee. "However, in our study we found that that BMK1 interacts with PML and suppresses its antitumor actions." To further investigate the BMK1-PML interaction, the researchers developed a compound called XMD8-92 that was remarkably selective at inhibiting BMK1.

Treatment with XMD8-92 blocked tumor cell proliferation and significantly inhibited tumor growth in mice. Importantly XMD8-92 had no obvious negative effects on the animals. "These results demonstrate that the BMK1 pathway can be blocked effectively by a small-molecule inhibitor without apparent adverse effects and, more importantly, BMK1 inhibition is a very effective way to prevent cancer development in animals," concludes Dr. Lee. "As BMK1 is expressed in most tumor cells, our results suggest that cancer therapies targeting BMK1 may be useful for treating diverse types of human tumors."


Contact: Cathleen Genova
Cell Press

Related medicine news :

1. Plant compound resveratrol shown to suppresses inflammation, free radicals in humans
2. Bone drug suppresses wandering tumor cells in breast cancer patients
3. Exosomal release of beta-catenin may explain why CD82 and CD9 suppress tumor metastasis
4. In-depth investigation on the capacity of 4-HPR to induce death of tumor cells
5. Tumor budding identified as predictor for unfavorable outcome in lung cancer
6. Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation
7. With muscle-building treatment, mice live longer even as tumors grow
8. Lung stem cells vital to lung repair associated with poor cancer prognosis when found in tumor
9. A lethal brain tumors strength may be a weakness as well
10. Merlin protein found to control liver stem cells, prevent tumor development
11. New drug reduces tumor size in women with advanced hereditary ovarian or breast cancer
Post Your Comments:
(Date:11/25/2015)... ... ... The holiday season is jam-packed with family dinners, parties ... is of the utmost importance. Whether you are cooking at home for the ... try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the ... loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and ... hair, without the need for surgery, prescription pills, or topical foams. , “Capillus272™ ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology: